-
1 Comment
GIMV NV is currently in a long term uptrend where the price is trading 5.7% above its 200 day moving average.
From a valuation standpoint, the stock is 3.3% more expensive than other stocks from the Financial Services sector with a price to sales ratio of 9.6.
GIMV NV's total revenue sank by 0.0% to $77M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $26M since the same quarter in the previous year.
Finally, its free cash flow grew by 9.0% to $-10M since the same quarter in the previous year.
Based on the above factors, GIMV NV gets an overall score of 2/5.
ISIN | BE0003699130 |
---|---|
Sector | Financial Services |
Industry | Asset Management |
Exchange | BR |
CurrencyCode | EUR |
Market Cap | 1B |
---|---|
PE Ratio | 5.56 |
Target Price | 50.6333 |
Dividend Yield | 6.5% |
Beta | 0.53 |
Gimv NV is a private equity and venture capital firm specializing in direct and fund of funds investments. For direct investments, the firm specializes in buyouts, growth capital, middle market, debt, shareholder loans, seed, startups, early to mid-stage, late venture, public to private transactions, small and medium sized enterprises, later stage, mature, replacement capital, bridge financing, and recapitalization. Within fund of funds, it seeks to invest in venture capital and private equity funds. It seeks to invest in high performance growth companies that respond to that can speed up their internal growth through acquisitions. The firm typically invests in consumer, connected consumer, fintech; health and care; smart industries; and sustainable cities. Within consumer, it seeks to provide growth capital to emerging leaders. Within health and care platform, the firm seeks to invest in companies that can grow either organically or through a buy and build strategy. Within consumer, it focuses on consumer goods, food and beverage, healthy food, sport, convenience food, personal luxury, career, home & deco, baby & kids, pet products, retail, consumer services, media and content, travel and leisure, education, digital economy and online sectors. Within health and care sector, it focuses on life sciences, medtech, and health and care services. The firm focuses on biotech/biopharma comprising drugs, platform technologies, vaccines and diagnostic tests, preclinical, early clinical, and late clinical, medtech such as medical devices, consumables, IT and small equipment, and health and care services-based companies. It also seeks to be an active shareholder, preferably lead or co-lead in its investments. Within smart industries, it focuses on equipment, services and tools for resource efficient development and production, automotive and aerospace, both optimizing of the existing and development of new means of transport, software and services harnessing the flexibility of the cloud, smart data management and advanced c
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for GIMB.BR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025